Cardiovascular Systems Stock News

Cardiovascular Systems Inc. (NASDAQ:CSII) shares, rose in value on Wednesday, 11/24/21, with the stock price up by 2.86% to the previous days close as strong demand from buyers drove the stock to $23.72. Actively observing the price movement in the last trading, the stock closed the session at $23.06, falling within a range of $22.6316 Cardiovascular Systems Inc. (NASDAQ:CSII) Will Likely Reach 40.00 USD! Read More »

Cardiovascular Systems, Inc. Initiates Voluntary Recall of WIRION® Embolic Protection System

Metropolitan Life Insurance Co NY raised its holdings in shares of Cardiovascular Systems, Inc. (NASDAQ:CSII) by 106,381.8% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 11,713 shares of the medical device companys stock after purchasing an additional 11,702 shares during the quarter. Metropolitan Life Insurance Co NYs holdings in Cardiovascular Systems were worth $500,000 []

Equities research analysts predict that Cardiovascular Systems, Inc. (NASDAQ:CSII) will announce sales of $62.71 million for the current quarter, according to Zacks Investment Research. Six analysts have made estimates for Cardiovascular Systems earnings, with estimates ranging from $61.30 million to $66.30 million. Cardiovascular Systems reported sales of $64.17 million in the same quarter last year, []

AMED, CSII, DVA, GFF, and LTRX have been added to the Zacks Rank #5 (Strong Sell) List on November 19, 2021.

According to Cardiovascular Systems (CSII), the resurgence of COVID-19 and the related staffing shortages are disrupting referral patterns and having the largest impact on elective procedures.

Schonfeld Strategic Advisors LLC bought a new position in Cardiovascular Systems, Inc. (NASDAQ:CSII) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 5,700 shares of the medical device companys stock, valued at approximately $243,000. Several other hedge funds have also recently modified their holdings of []

Cardiovascular Systems (NASDAQ:CSII) had its target price cut by SVB Leerink from $45.00 to $40.00 in a report issued on Wednesday, Price Targets.com reports. They currently have an outperform rating on the medical device companys stock. SVB Leerink also issued estimates for Cardiovascular Systems Q2 2022 earnings at ($0.09) EPS, Q3 2022 earnings at ($0.04) []

ALTO, CSII, DELL, PRPL, and WRK have been added to the Zacks Rank #5 (Strong Sell) List on November 12, 2021

Cardiovascular Systems' (CSII) coronary franchise registers strong performance globally on continued strength in Japan and Europe.

Cardiovascular Systems, Inc. (CSII) CEO Scott Ward on Q1 2022 Results - Earnings Call Transcript

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -120.00% and -7.80%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the

Cardiovascular Systems' (CSII) ViperCross offers the correct balance of support and flexibility to navigate tortuous anatomy and cross challenging lesions.

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. ANNOUNCES FIRST PATIENT TREATED WITH VIPERCROSS™ PERIPHERAL SUPPORT CATHETER